Ayat G Lashen
Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study
Lashen, Ayat G; Toss, Michael; Miligy, Islam; Rewcastle, Emma; Kiraz, Umay; Janssen, Emiel A M; Green, Andrew R; Quinn, Cecily; Ellis, Ian; Rakha, Emad
Authors
Michael Toss
Islam Miligy
Emma Rewcastle
Umay Kiraz
Emiel A M Janssen
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Cecily Quinn
Ian Ellis
EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Abstract
Aims
In this study, we validate the use of Nottingham Prognostic x (NPx), consisting of tumour size, tumour grade, progesterone receptor (PR) and Ki67 in luminal BC.
Materials and methods
Two large cohorts of luminal early-stage BC (n = 2864) were included. PR and Ki67 expression were assessed using full-face resection samples using immunohistochemistry. NPx was calculated and correlated with clinical variables and outcome, together with Oncotype DX recurrence score (RS), that is frequently used as a risk stratifier in luminal BC.
Results
In the whole cohort, 38% of patients were classified as high risk using NPx which showed significant association with parameters characteristics of aggressive tumour behaviour and shorter survival (P < 0.0001). NPx classified the moderate Nottingham Prognostic Index (NPI) risk group (n = 1812) into two distinct prognostic subgroups. Of the 82% low-risk group, only 3.8% developed events. Contrasting this, 14% of the high-risk patients developed events during follow-up. A strong association was observed between NPx and Oncotype Dx RS (P < 0.0001), where 66% of patients with intermediate risk RS who had subsequent distant metastases also had a high-risk NPx.
Conclusion
NPx is a reliable prognostic index in patients with luminal early-stage BC, and in selected patients may be used to guide adjuvant chemotherapy recommendations.
Citation
Lashen, A. G., Toss, M., Miligy, I., Rewcastle, E., Kiraz, U., Janssen, E. A. M., Green, A. R., Quinn, C., Ellis, I., & Rakha, E. (2024). Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study. Histopathology, 85(3), 468-477. https://doi.org/10.1111/his.15234
Journal Article Type | Article |
---|---|
Acceptance Date | May 28, 2024 |
Online Publication Date | Jun 13, 2024 |
Publication Date | 2024-09 |
Deposit Date | Aug 16, 2024 |
Publicly Available Date | Aug 19, 2024 |
Print ISSN | 0309-0167 |
Electronic ISSN | 1365-2559 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 85 |
Issue | 3 |
Pages | 468-477 |
DOI | https://doi.org/10.1111/his.15234 |
Public URL | https://nottingham-repository.worktribe.com/output/38382506 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1111/his.15234 |
Files
Main Text (clean Version)
(694 Kb)
PDF
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search